knowledge -WSS

knowledge

author：comprehensive 2025-10-01 18:45:12 - browse：75

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

hotspot

WSS

This gene therapy has record $4.25 million price. It's saved children.

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Congress may force more Covid

Yancopoulos of Regeneron works to expand Dupixent success

Texas board proposes rules on abortion law emergency exemption

Bring on the sabbaticals for nurses

explore

knowledge

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Mirador, a new biotech startup, launches with $400 million

The high cost of giving birth even with insurance

Asbestos ban is immediate, but health effects will linger for decades

State Dept. review finds Biden bears some blame for Afghanistan failures

WATCH: Why do our ears pop?

Medical leaders decry Supreme Court decision on affirmative action

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Walensky prepares to leave CDC — and Congress — behind

Asbestos ban is immediate, but health effects will linger for decades

leisure time

Adam's Take: Intra

This gene therapy has record $4.25 million price. It's saved children.

Secretariat’s lessons for human medicine

WATCH: Why do our ears pop?

Medicare Advantage insurers pressure Biden for bigger payments

A new drug could help frostbite victims avoid its ravages

knowledge

explore

hotspot

leisure time